by Kyle Dennis | Jun 22, 2017 | Biotech Stocks
The back story: I have never traded the iShares Nasdaq Biotechnology ETF, but I monitor it as a gauge on when to get into or out of individual names. That said, some traders prefer to play the ETF rather than a few of the underlying stocks themselves. Why others are...
by Jeff Bishop | Jun 22, 2017 | Biotech Stocks
The news: The Senate reveals its plans to replace ObamaCare today. Like seemingly everyone else, it has me looking at health-care and biotech stocks. My investment thoughts about the news: Sell health-care provider stocks like Aetna (AET) and Cigna (CI), and buy...
by Kyle Dennis | Jun 15, 2017 | Biotech Stocks
On the watch: Versartis Inc. (VSAR) What put it on my radar screen: I look for data events and VSAR has a Phase III trial readout in September for a growth-hormone deficiency drug called VRS-317. This is the results of a 12-month trial, and there’s plenty of time...
by Kyle Dennis | Jun 13, 2017 | Biotech Stocks
The stories you are about to hear are true. However, the names have been changed to protect the innocent. Now, it’s great that you decided to keep a trading journal, it’s an excellent way to review and learn about your trading decisions. The problem is a lot of you...
by Kyle Dennis | Jun 12, 2017 | Biotech Stocks
Successful people know that luck has very little to do with it. In fact, many will tell you that they planned to succeed. Believe it or not, as random as the stock market is, planning is essential to your results. I remember once, talking to a new trader about Apple...
by Kyle Dennis | Jun 9, 2017 | Biotech Stocks
Have you ever read a Form 10-K filing? Well, it’s an annual report that publicly-traded companies are required to complete, in order to be in compliance with U.S. Securities and Exchange Commission. For the most part, the first section outlines the nature of the...
by Kyle Dennis | May 8, 2017 | Biotech Stocks
Horizon Pharma PLC (NASDAQ: HZNP) reported its first quarter 2017 financial results today, and the company missed the Street’s revenue and EPS estimate. Not only that, but the company lowered its revenue, and adjusted earnings before interest, taxes, depreciation and...
by Kyle Dennis | May 8, 2017 | Biotech Stocks
PAREXEL International Corp (NASDAQ: PRXL) shares were up over 7%, after it was announced that the drug-research company hired investment bankers to explore a sale, according to The Wall Street Journal. Now, this report comes after the company reported its third...
by Kyle Dennis | May 2, 2017 | Biotech Stocks
Sunesis Pharmaceuticals Inc (NASDAQ: SNSS) announced that the company is expecting to withdraw from its European Marketing Authorization Application (MAA) for vosaroxin, for the treatment for relapsed/refractory acute myeloid leukemia in patients who are over the age...
by Kyle Dennis | May 1, 2017 | Biotech Stocks
Neurotrope Bioscience (NASDAQ: NTRP) shares fell over 60%, after the company announced data from its Phase II study of Bryostatin-1 for the treatment of moderate to severe alzheimer’s disease. Now, the company tried to spin the press release, but traders were able to...
by Kyle Dennis | Apr 30, 2017 | Biotech Stocks
Athenahealth Inc (NASDAQ: ATHN) shares were down nearly 20% on the day, after the healthcare company cut its guidance and missed consensus estimates last night. With the weakened outlook for the 2017 fiscal year, there was selling pressure in the stock. However, it...
by Kyle Dennis | Apr 27, 2017 | Biotech Stocks
EXACT Sciences Corporation (NASDAQ: EXAS) shares were up over 20% today after the company provided guidance and topped its earnings estimates. Now, the company’s raised guidance could be an indication that the stock could potentially continue to rise this year. Let’s...
by Kyle Dennis | Apr 26, 2017 | Biotech Stocks
Akebia Therapeutics Inc. (NASDAQ: AKBA) shares were up over 30% today after it announced it expanded its collaboration with Otsuka Pharmaceutical, for vadaustrat. Now, the companies entered into a collaboration and license agreement for China, Europe and other...
by Kyle Dennis | Apr 25, 2017 | Biotech Stocks
Express Scripts (NASDAQ: ESRX) shares were down over 10% on the day, after the company announced that Anthem intends to shift its business when the current long-term PBM contract expires on December 31, 2019. Let’s take a look at the company’s 1Q 2017 results first,...
by Kyle Dennis | Apr 24, 2017 | Biotech Stocks
XOMA Corporation (NASDAQ: XOMA) shares ended the day down just over 8%, despite releasing positive Phase II proof-of-concept results for X213 in physiological hyperprolactinemia (HPRL). Now, we’ll get to that later, but, first, let’s see why shares slid today. XOMA...
